A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab in Vials Manufactured by Two Different Processes

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Risankizumab (Primary)
Indications Atopic dermatitis; Crohn's disease; Erythrodermic psoriasis; Generalised pustular psoriasis; Hidradenitis suppurativa; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

02 May 2024 Status changed from active, no longer recruiting to completed.
19 Dec 2023 Planned End Date changed from 29 Jun 2024 to 4 Jul 2024.
19 Dec 2023 Planned primary completion date changed from 29 Jun 2024 to 4 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com